Weaver Capital Management’s Edwards Lifesciences EW Stock Holding History

Weaver Capital Management’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$632K	Sell	7,322 -1,451	-17%	-$129K	0.12%	118
2026 Q2	$703K	Hold	8,773	–	–	0.15%	113
2026 Q1	$703K	Sell	8,773 -976	-10%	-$80.5K	0.15%	115
2025 Q4	$831K	Sell	9,749 -97	-1%	-$7.96K	0.18%	114
2025 Q3	$766K	Sell	9,846 -747	-7%	-$58.4K	0.17%	111
2025 Q2	$828K	Sell	10,593 -205	-2%	-$15.3K	0.2%	107
2025 Q1	$783K	Buy	10,798 +110	+1%	+$7.87K	0.21%	106
2024 Q4	$791K	Buy	10,688 +5,560	+108%	+$389K	0.22%	108
2024 Q3	$338K	Sell	5,128 -5,525	-52%	-$401K	0.1%	139
2024 Q2	$984K	Sell	10,653 -155	-1%	-$13.7K	0.32%	84
2024 Q1	$1.03M	Buy	10,808 +2,890	+36%	+$243K	0.35%	80
2023 Q4	$604K	Buy	+7,918	New	+$551K	0.24%	90

Other funds holding EW

Ninety One (UK) London, United Kingdom $45.5B AUM 15.2% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Parnassus Investments San Francisco, California $33.8B AUM 31.08% 1-Year Est. Return

DekaBank Deutsche Girozentrale Frankfurt, Germany $87.8B AUM 20.94% 1-Year Est. Return

Birch Hill Investment Advisors Boston, Massachusetts $2.43B AUM 15.45% 1-Year Est. Return

KBC Group Brussels, Belgium $47.9B AUM 37.61% 1-Year Est. Return

Seilern Investment Management London, United Kingdom $771M AUM 2.59% 1-Year Est. Return

Ninety One North America New York $2.13B AUM 8.8% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $83.2B AUM 35.34% 1-Year Est. Return

ABN AMRO Investment Solutions Paris Cedex 008 $13.2B AUM 30.55% 1-Year Est. Return

Weaver Capital Management's EW Position: Q3 2026 in Review

Weaver Capital Management reduced its Edwards Lifesciences (EW) stake by 17% in Q3 2026, selling an estimated $129K and leaving 7,322 shares worth $632K. The position accounts for 0.12% of the portfolio, ranked #118.

Weaver Capital Management first reported a position in EW in Q4 2023 and has held it in 12 quarters since. The position peaked at $1.03M in Q1 2024. 402 funds tracked by Wall St. Rank hold EW as of Q3 2026.

Weaver Capital Management held 7,322 shares of Edwards Lifesciences worth $632K as of Q3 2026.
Weaver Capital Management sold 1,451 Edwards Lifesciences shares in Q3 2026, an estimated $129K.
Edwards Lifesciences made up 0.12% of Weaver Capital Management's portfolio in Q3 2026, its #118 holding.
Weaver Capital Management first reported a position in Edwards Lifesciences in Q4 2023 and has held it in 12 quarters since.
Weaver Capital Management's Edwards Lifesciences position peaked at $1.03M in Q1 2024.
402 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q3 2026.

Based on Weaver Capital Management's 13F filing for Q3 2026, filed 15 Oct 2026.